Trexquant Investment LP Invests in ResMed Inc
December 11, 2023
🌥️Trending News
RESMED ($NYSE:RMD): Trexquant Investment LP has recently acquired a stake in ResMed Inc. ResMed Inc is a leading global health technology company that produces medical devices and software solutions for the diagnosis, treatment, and management of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Its products and solutions are designed to improve the lives of those with respiratory conditions, aiming to help people breathe better and live healthier.
Through its innovative technology, comprehensive services, and data-driven insights, ResMed is committed to providing solutions that help people get the most out of life. Trexquant Investment LP’s acquisition of a stake in ResMed Inc reflects their confidence in the company’s future performance and potential to continue providing groundbreaking solutions to those with chronic respiratory conditions.
Market Price
On Monday, Trexquant Investment LP announced its investment in ResMed Inc, a leading global medical device company. Following the news, the stock of RESMED INC opened at $152.7 and closed at $152.6, down by 0.9% from its prior closing price of 153.9. The investment has made Trexquant a new significant shareholder in ResMed Inc, and they are expecting considerable returns from the company in the coming future. In addition to the Trexquant Investment, other major investors in ResMed Inc include Baillie Gifford & Co, BlackRock Inc., and Vanguard Group Inc., amongst others. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Resmed Inc. More…
| Total Revenues | Net Income | Net Margin |
| 4.38k | 906.5 | 20.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Resmed Inc. More…
| Operations | Investing | Financing |
| 934.92 | -1.25k | 313.62 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Resmed Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.74k | 2.49k | 28.9 |
Key Ratios Snapshot
Some of the financial key ratios for Resmed Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 13.1% | 10.9% | 26.6% |
| FCF Margin | ROE | ROA |
| 18.1% | 17.4% | 10.8% |
Analysis
GoodWhale conducted an analysis of RESMED INC‘s financials, which resulted in a high health score of 9/10 with regard to its cashflows and debt. This score indicates that RESMED INC is capable of safely riding out any crisis without the risk of bankruptcy. Furthermore, RESMED INC is classified as a ‘gorilla’ – a type of company that has achieved stable and high revenue or earnings growth due to its strong competitive advantage. Given these positive characteristics, we believe that RESMED INC would be attractive to investors seeking dividend, growth, and profitability. The company also has a medium score for its assets, indicating that it is well-positioned to generate further returns in the future. We recommend investors who are looking for a safe and consistent bet to consider RESMED INC as their investment choice. More…
Peers
ResMed’s competitors include Natus Medical Inc, Sanara MedTech Inc, and Avita Corp.
– Natus Medical Inc ($NASDAQ:SMTI)
As of 2022, Sanara MedTech Inc has a market cap of 227.36M and a Return on Equity of -22.91%. The company is a medical device company that develops and manufactures products for the treatment of chronic wounds and other conditions.
– Sanara MedTech Inc ($TPEX:4735)
Avita Corp is a biotechnology company that develops, manufactures, and markets products based on regenerative medicine. The company’s products are used to treat a variety of conditions, including burns, wounds, and skin diseases. Avita’s products are sold in over 30 countries worldwide. The company has a market cap of 1.21B as of 2022 and a return on equity of 9.62%.
Summary
Trexquant Investment LP recently purchased a significant stake in ResMed Inc, which is a global leader in connected care medical device solutions. This investment is an indication of confidence in the company’s future prospects. In the short-term, analysts predict that ResMed’s share price will benefit from recently announced product launches. On the long-term, the company’s continued investments in research and development could result in innovative products that could lead to substantial growth. ResMed has also made significant investments in implementing software solutions to further improve patient care.
Additionally, the company’s market presence in the sleep therapy industry should help drive growth in the years ahead. Ultimately, this new investment should be a positive sign for investors interested in ResMed Inc.
Related Posts
Recent Posts
